PCRX vs SPG · P/E 174, rev $369.8M vs rev $3.55B
Pacira BioSciences, Inc. (PCRX) versus SPG (SPG) — a side-by-side from cached financials, not a winner call.
Pacira BioSciences, Inc. (PCRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
SPG (SPG) common stock.
Latest reported PCRX revenue for 2026-06-30 was $369.8M. Net income was $7.6M. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
Latest reported SPG revenue for 2026-06-30 was $3.55B. Net income was $1.14B. SPG currently screens at market cap $0.
PCRX currently screens at market cap $890.8M and trailing P/E 174.2. SPG currently screens at market cap $0.
Not investment advice. Open the PCRX and SPG stock pages for the full models.
Not investment advice.